Related Experiment Video
Updated: Jun 5, 2025
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
460
[The new generations of CAR-T cells]
Djamel Messaoudi1, Franck Perez1, Zélia Gouveia2
1Dynamics of intracellular organization laboratory, Institut Curie, PSL Research University, Sorbonne Université, CNRS, UMR144, Paris, France.
Medecine Sciences : M/S
|December 10, 2024
Summary
Chimeric antigen receptor (CAR)-T cell therapy engineers immune cells to fight cancer. This review details CAR generations, from early versions to advanced 5th generation therapies, addressing challenges in cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy represents a significant advancement in cancer immunotherapy.
- Recent successes have led to FDA approval for treating hematologic malignancies.
Purpose of the Study:
- To provide a comprehensive overview of the evolution of CAR generations.
- To discuss the advancements in CAR T-cell therapy for various cancers and autoimmune diseases.
Main Methods:
- Review of scientific literature on CAR T-cell therapy development.
- Analysis of different CAR generations and their biological activities.
- Discussion of clinical trial progress and limitations.
Main Results:
- CAR T-cell therapy has evolved through five generations, enhancing efficacy and safety.
- Early CAR generations showed limited cytotoxic activity, while later generations aim to overcome persistence and toxicity issues.
- Ongoing trials explore CAR T-cell applications in solid tumors and autoimmune diseases.
Conclusions:
- CAR T-cell therapy is a rapidly advancing field with significant potential in oncology.
- Further research and development are crucial to address limitations, particularly for solid tumor treatment.
- The evolution of CAR generations signifies progress towards more effective and safer immunotherapies.
